Cell & Gene Unscripted: Honest conversations with the experts shaping what's next
Cell and gene therapy isn't advanced by easy answers. It's advanced by difficult choices, evolving science, and the people willing to challenge assumptions. This series explores what those decisions mean and what's at stake.
Hosted by Parexel's Head of Cell & Gene Therapy and Early Phase, Chris Learn, Ph.D. M.B.A., P.M.P., this exclusive video series brings together industry leaders to unpack the trade-offs, tensions, and opportunities shaping the future of the field, from regulatory strategy and trial execution to patient access and real-world evidence.
No rehearsed talking points. No surface-level perspectives. Just honest discussions designed to help biotech and biopharma leaders navigate an increasingly complex landscape.
Related Insights
Article
Preparing early for acquisition: how biotech companies can build value long before a deal
Nov 20, 2026
Article
Data first, trial second: Rethinking evidence generation in rare disease
Nov 18, 2026
Blog
Beyond automation: Redesigning pharmacovigilance for the age of AI
Nov 16, 2026
CTB Podcast
Putting Patients First: Kirk Taylor on Clinical Trials, Trust, and Access to Medicines
Nov 2, 2026
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Blog
Adapting at the pace of development: Why operating model flexibility is key to success
Oct 21, 2026
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
Article
AI at clinical sites: Practical tips for safe & effective use
Oct 13, 2026
Blog
The next generation of FSP will be defined by results, not headcount
Oct 8, 2026
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
Related Insights
Article
Preparing early for acquisition: how biotech companies can build value long before a deal
Nov 20, 2026
Article
Data first, trial second: Rethinking evidence generation in rare disease
Nov 18, 2026
Blog
Beyond automation: Redesigning pharmacovigilance for the age of AI
Nov 16, 2026
CTB Podcast
Putting Patients First: Kirk Taylor on Clinical Trials, Trust, and Access to Medicines
Nov 2, 2026
Blog
FDA's revised effectiveness guidance: What it means for evidence strategy and real-world research
Oct 29, 2026
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
Blog
Adapting at the pace of development: Why operating model flexibility is key to success
Oct 21, 2026
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
Article
AI at clinical sites: Practical tips for safe & effective use
Oct 13, 2026
Blog
The next generation of FSP will be defined by results, not headcount
Oct 8, 2026
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026

